Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (May 2025)
13 slides from Pyc Therapeutics's investor presentation, May 30, 2025
Slide 1: Q2 Investor Webinar
For personal use only Life-changing science Q2 Investor Webinar May 2025
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Any forward-looking statements in this presentation have been prepared on the For personal use only Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a basis of a number of assumptions
Slide 3: Objectives for today
Objectives for today For personal use only 1) Provide a detailed update on each of PYC’s pipeline program updates a) Progress (year to date) b) Objectives for the remainder of 2025 2) Outline the platform implications of near-term program milestones 3) Contextualise PYC’s progress within the broader
Slide 4: An introduction to PYC
For personal use only Life-changing science An introduction to PYC
Slide 5: An introduction to PYC – differentiated drug development
An introduction to PYC – differentiated drug development 1 2 3 4 5 For personal use only Disease-modifying In areas of major With the highest Validated in patient- Generating human drug candidates unmet need probability of success derived models efficacy data in 2025 5x Each of PYC’s pipeline In a d
Slide 6: PYC has built a pipeline of drug candidates with the potential to become the standard of care
PYC has built a pipeline of drug candidates with the potential to become the standard of care in areas of major unmet need Historical progress Progress expected in 20251 For personal use only Program Pre-clinical Clinical Prevalence2 VP-0013 Retinitis Pigmentosa Type 11 1 in 100,000 PYC-001 Autosoma
Slide 7: Program-level updates
For personal use only Life-changing science Program-level updates
Slide 8: All development programs in PYC's pipeline are on track to deliver on their 2025 objectives
All 4 development programs in PYC’s pipeline are on track to deliver on their 2025 objectives 2025 2026 For personal use only Program RP11 Ph1/2 study VP-001 1 Clinical proof-of-concept Monogenic blinding eye disease of childhood Open-label extension of Ph Registrational study Gene: PRPF31 1/2 study
Slide 9: Platform milestones
For personal use only Life-changing science Platform milestones
Slide 10: Upcoming clinical milestones will also help validate PYC's delivery platform
Upcoming clinical milestones in each of PYC’s programs will also help validate PYC’s delivery platform 2025 2026 For personal use only Program RP11 Ph1/2 study VP-001 1 Clinical proof-of-concept 1 Monogenic blinding eye disease of childhood Open-label extension of Ph Registrational study Gene: PRPF3
Slide 11: When to deal
For personal use only Life-changing science When to deal
Slide 12: Maximising value from the pipeline
Maximising value from the pipeline For personal use only 1. Stifel Building Value in Biotech February 2024 PYC THERAPEUTICS 12
Slide 13: Q&A
For personal use only Life-changing science Q&A